Although both rat cardiac nonmyocytes (mostly fibroblasts) and cardiomyocytes have a functional angiotensin II (AngII) receptor, the regulation mechanism of its subtype expression in the rat heart remains unknown. In this study, by using a binding assay and a competitive reverse-transcriptase polymerase chain reaction, we examined the regulation of AngII types la and lb (ATla-R and AT1b-R) and type 2 receptor (AT2-R) expression in embryonal day 19 (E19) and neonatal (1-d) rat cardiac fibroblasts and cardiomyocytes. The number of AT2-R in E19 fibroblasts was dramatically decreased (from 305 to 41 fmol/mg protein) in 1-d fibroblasts, whereas that of AT1-R and the mRNA levels remained unchanged. The ratio of ATla-R to AT1b-R mRNA in both E19 and 1.4 fibroblasts was 9:1. The number of AT2-R in E19 cardiomyocytes was also significantly decreased (from 178 to 87 fmol/mg protein) in 1-d cardiomyocytes, whereas the magnitude was less prominent compared with that in fibroblasts. AT1-R expression remained unaltered in E19 and 1-d cardiomyocytes. In E19 and l-d cardiomyocytes, the ATlb-R mRNA level was 1.5-fold higher than that of AT1a-R mRNA. Dexamethasone induced significant increases in AT1a-R mRNA (2.1-fold) and numbers (1.8-fold) without changing the affinity, whereas neither AT1b-R mRNA nor the number of AT2-R was affected by dexamethasone. The ATla-R gene transcription rate, determined by means of a nuclear run-off assay, was increased (2-fold) by dexamethasone. The half-life of ATla-R mRNA (18 h) was unchanged by dexamethasone. These data indicate that AngI1 receptor subtype expression in the rat heart is regulated in a cell-and subtype-specific manner. (J. Clin. Invest. 1994. 
Introduction
Angiotensin II (AngII)1 has multiple physiological effects directly and indirectly on the cardiovascular system that are initi-1. Abbreviations used in this paper: ACE, angiotensin-converting enzyme; ANF, atrial natriuretic factor; AngIl, angiotensin II; AT1-R, AngII type 1 receptor; AT2-R, AngII type 2 receptor. ated by binding to specific receptors located on the plasma membrane (1) . Recently, two benzylimidazole derivatives have been used to distinguish AngII receptor subtypes in several tissues. Dup 753 and TCV-1 16 inhibits the AnglI type 1 receptor (ATI-R), which is the predominant subtype in the adrenal cortex, vasculature, kidney, and liver, whereas PD123319 and CGP421 12A inhibit the AngII type 2 receptor (AT2-R), present in the adrenal medulla, uterus, a subset of brain nuclei, and ovary of the adult animal (for review see reference 2) . Both AT1-R and AT2-R subtypes are equally distributed over the myocardium (3, 4) . The cloning of rat (5-7), bovine (8) , human (9) (10) (11) , and mouse (12) ATI-R cDNA has made it possible to study the AT I -R gene expression mechanism in the heart at the molecular level. The AT I-R cDNA cloned from bovine adrenal cells (8) and rat vascular smooth muscle cells (5) was termed AT 1 a-R. The second form of ATI-R (AT lb-R), which exhibited highly homologous sequences and similar binding and functional characteristics, was cloned from the rat pituitary (12) and adrenal glands (7) . These subtypes are widely expressed in various rat tissues and the differential tissue-specific regulation of the mRNAs was reported (7, 13) .
AngIl directly stimulates heart rate, cardiac contractility, and growth ( 14) . Subnanomolar concentrations ofAngIl facilitates adrenergic neurotransmission in the heart ( 15) , indirectly leading to an increase in the heart rate, contractility, and a decrease in coronary flow ( 15, 16) . The majority ofthe cardiovascular and hormone modulating actions ofAng1I in the adult animal are mediated through the ATI-R (2). Grady et al. ( 17) have reported that the AT2-R is highly expressed in the mesenchymal tissue ofthe developing rat fetus and rapidly disappears after birth. Similarly, it has been shown that during embryonic and immediate postnatal development rat aortic smooth muscle cells express AT2-R almost exclusively ( 18) . These findings indicate an AT2-R mediating effect of AnglI in tissue growth and development during the embryonic period. In the rat heart, we (3) and others (4) have demonstrated that AngII receptor expression is increased during the neonatal period and decreases with maturation, that the expression of AT 1 -R and AT2-R is nearly equal in the rat myocardium, and that the proportion is unchanged through development. However, a number of cell types are present in the heart, in which cardiomyocytes and cardiac fibroblasts are the predominant cell types in the neonatal rat heart ( 19) . Cultured cardiomyocytes as well as cardiac fibroblasts prepared from the neonatal rat heart are immunoreactive to AngII, AngI, and angiotensinconverting enzyme (ACE) (20) . Although previous studies have reported the presence of high-affinity AngII binding sites in cardiac tissues ( 3, 21 ), which cardiac cell types are responsible for the binding sites has not been determined. Schorb et al. (22) have shown that neonatal rat cardiac fibroblasts express a substantial amount of AT I -R rather than AT2-R. In addition, recent studies have also reported that isolated adult rat cardiomyocytes exclusively exhibit the AT1-R subtype (23) and that AT l-R mediates AngIlI-induced hypertrophy of cardiomyocytes (24) . Thus, the subtype expression profiles in isolated heart cells appears distinct from those in cardiac tissue. We therefore examined the cell-type specific developmental regulation in AT I-R (AT la and ATlb) and AT2-R expression using cultured rat cardiomyocytes and cardiac fibroblasts. The result demonstrated that ATI-R and AT2-R expression is differentially regulated during perinatal development in a cell typespecific manner.
It has been reported that AngIl receptor levels in the anterior pituitary gland are strongly inhibited by estrogens (25).
Kakar et al. ( 13) have demonstrated that AT I b-R mRNA levels, but not those of AT 1 a-R, are suppressed by estrogen in the pituitary gland. Kambayashi et al. (25) have shown that the expression of AT2-R is downregulated in cultured smooth muscle cells by growth factors, in contrast to that of AT I-R, which was slightly upregulated. These findings suggest that AngIl receptor mRNA regulation is not in the static state. Glucocorticoids are involved in the regulation of blood pressure (27) , in which enhancement of vascular responsiveness has been considered one of the major contributing factors (28) . We examined the effect of dexamethasone on the AT1-R mRNAs (AT la-R and AT lb-R) and AT2-R regulation. The results demonstrated that the AT 1 a-R gene responds to dexamethasone at the transcriptional level, whereas AT1b-R and AT2-R were not affected by dexamethasone.
Methods
Cell cultures. Enriched cultures of cardiomyocytes and cardiac nonmyocytes were prepared from hearts of embryonal day 19 (El9) and neonatal (day 1 or 7) Wistar rats. All steps were basically performed according to the method published by Dostal et al. (20) . The rats were decapitated, and the hearts were removed and placed in HBSS. For each dispersion, hearts from -250 rats were minced and digested with 5% pancreatin (vol/vol) and 0.32 mg/ml collagenase II in HBSS with 12.5 mM Hepes. The supernatant from the first step of the digestion procedure (1O min) containing cell debris and red blood cells was discarded. Cells from the eight subsequent digestions (20 min each) were collected in 50-ml sterile polypropylene tubes containing 20 ml of Dulbecco's modified essential medium (DMEM) with 20% FCS and sedimented by centrifugation at 200 g for 4 min. The cell pellets, which consisted primarily of cardiomyocytes and cardiac nonmyocytes, were resuspended in 60 ml of DMEM with 20% FCS. The cell suspensions were combined and incubated for 90 min at 370C in 25- cm2 flasks, which allowed for selective attachment of nonmyocytes.
Since most of nonmyocyte-enriched cultures consist of fibroblasts ( 19, 20, 22, 24) , the cultures are hereafter referred to as fibroblast cultures. Cardiomyocyte-enriched suspensions were removed from the culture dishes and replaced with DMEM containing 10% FCS. The culture dishes containing attached fibroblasts were placed into an incubator and passaged 48 h later with 0.25% trypsin. The fibroblasts were plated in DMEM containing 10% FCS at a density of 3-5 X 103 cells/cm2 on 100-mm dish and 35-mm dish or in six-well plastic cell culture dishes containing 22- (3) .
Quantitative reverse transcription (R T) and PCR assay. Firststrand cDNA was synthesized from total RNA, as reported for AT1a-R mRNA in rat ventricles (3) . Total RNA was isolated by means of guanidium isothiocyanate-cesium chloride centrifugation followed by digestion with DNase (Takara Shuzo, Kyoto, Japan) to remove contaminating genomic DNA. The following PCR oligonucleotide primers (0.5 MM) were designed from the cDNA sequences common to ATla-R (5) and AT Ib-R (7): sense from the 5'codingregion (5'-GGA-AACAGCTTGGTGGTG-3') and antisense from the coding region (5'-GCACAATCGCCATAATTATCC-3'). These primers corresponded to the regions where no sequence divergence was noted between ATla-R and ATIb-R. To obtain deletion mutated cRNA (/AT I -R), the 607-bp PCR product was treated with T4 polynucleotide kinase (Takara Shuzo) and blunt-ended with Klenow DNA polymerase (Takara Shuzo) for subcloning into the EcoRV site of pBluescript II KS( -) (Stratagene Inc., La Jolla, CA). The plasmid was cut by MscI and self-ligated to contain an insert lacking MscI-MscI (288 bp). The deletion-mutated cRNAswere synthesized usingT7 RNA polymerase (Takara Shuzo) after being linearized with Hind III. Total RNA (500 ng) and the deletion-mutated cRNA (1 pg) were simultaneously mixed and assayed by competitive RT-PCR. Denaturing, annealing, and extension reactions were performed 25 times at 940C for'45 s, 60'C for 30 s, and 720C for 1 min, respectively. Native ATIa-R and AT1 b-R mRNA should give a 607-bp DNA fragment and the deletion mutated cRNA should give that of 419 bp. Contamination by genomic DNA in sample RNAs was circumvented by amplifying the sample RNAs directly to PCR without RT, in which no significant product was visible after 40 cycles. The specificity of the gene amplification was confirmed by the specific restriction digestion pattern with Hae III as reported by Iwai and Inagami (7) . As an internal RNA control, 5'-end labeled rat a-tubulin probe was used for Northern blotting as previously reported (3) . The autoradiographic signals were measured by a scanning densitometer. To quantify the AT I-R mRNA, a trace amount (5 MCi) of [32P]dCTP was included in the PCR reaction mixture. The bands of interest were excised from the agarose and 32P incorporation was measured in a scintillation counter. To control for the efficiency of RT-PCR amplification against tube-to-tube variation and the variability in the amount of input RNA, the 32P count in ATI-R signal was normalized to both the 32P counts in the deletion-mutated cRNA signal and the a-tubulin counts measured by the scanning densitometer. The normalized value in an appropriate control was expressed as 1 arbitrary unit for quantitative comparison.
AT I a-R or AT I b-R mRNA was amplified with the oligonucleotide primers specific for the respective 3'-noncoding sequences as reported by Kitami et al. (30) : sense and antisense for ATla-R, 5'-GCACAC-TGGCAATGTAATGC-3' and 5'-GTTGAACAGAACAAGTGACC-3', respectively; and sense and antisense for ATlb-R, 5'-GCCTGC-AAGTGAAGTGATTT-3' and 5'-T1-lTAACAGTGGCTTTGCTCC-3', respectively. Denaturing, annealing, and extension reactions were performed 30 times at 94°C for 30 s, 58°C for 45 s, and 72°C for 1 min. The RT-PCR products were 385 bp for ATIa-R and 204 bp for ATlb-R. The specificity of gene amplification was confirmed by reading the DNA sequence by direct sequencing using assymetrical PCR (31) . To determine the ratio of the AT I a-R and AT lb-R mRNA levels, a trace amount (5 MCi) of [32P]dCTP was included in the PCR, then the resultant amplified fragments were excised from the gel and the incorporated 32P counts were measured in a scintillation counter.
Nuclear run-off transcription assay. Nuclei were prepared from dexamethasone-treated or control cardiac fibroblasts and a run-off assay was performed as described elsewhere (32) . Nuclei (3-5 X 10') were incubated for 20 min at 30°C in the presence of 50 mM Tris, pH 7.9, 100 mM KCI, 12.5% glycerol, 6 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 4 mM of ATP, GTP, and CTP, 1 U/Mi RNAsin, and 200 MuCi of [a-32P]UTP. After RNase-free DNase I and proteinase K digestion, the reaction products were extracted with guanidinium isothiocyanate (4 M) and phenol/chloroform, and unincorporated [a-32P]-UTP was removed by trichloroacetic acid precipitation and filtration.
The radiolabeled RNA (2-3 X I0' cpm) wasdissolved in 1 ml ofhybridization solution (50% formamide, 5 X SSC, 160 mM Tris, pH 7.5, 1 X Denhardt's solution, 0.5% SDS, 7.5% Dextran) and hybridized at 42°C for 48 h with 5 Mug of linearized pBluescript II KS( -) plasmid, immobilized to a nylon membrane, containing rat ATla-R cDNA fragment (3) or rat #l-actin cDNA (a kind gift from Dr. Yasukiyo Mori, Kansai Medical University, Japan). After washing the membrane in 2 X SSC + 0.1% SDS at 65°for I h,0.2 x SSC + 0.1% SDS at 37°C for 30 min in the presence of 10 Mg/ml RNase A, and 0.2 X SSC at 37°C for 30 min, the bound radioactivity was determined by scintillation counting.
Transcription stability analysis. The stability of ATla receptor mRNA in dexamethasone-treated and control cardiac fibroblast was measured by incubating the cells with 5 Mg/ml actinomycin D to block transcription as reported previously (33) . After various periods of incubation, total RNA (2 Mg) was isolated from individual dishes and RT-PCR was performed using the primers specific for ATla receptor gene without deletion mutated cRNA.
Immunocytochemistry. The contamination of cardiomyocytes was examined by means of the immunofluorescent staining using a mouse monoclonal antibody against desmin (Sigma Chemical Co., St. Louis, MO), a cytochemical protein ofcardiomyocytes as described by Dostal et al. (20) . The staining procedures were performed on cells seeded on glass coverslips. After aspirating of culture media, cells were washed three times with 100 mM glycine in PBS (12.3 mM NaH2PO4, 3 .17 mM KH2PO4, 123.3 mM NaCI, pH 7.4) and fixed for 10 min at 22°C with Formalin fixative (3.7% formamide, 244 mM sodium acetate, pH 7.5). The cells were washed three times with 100 mM glycine in PBS and soaked in 0.05% Triton X-100 in PBS for 10 min. The cells were washed and incubated with the solution containing 50 mM Tris pH 7.4, 100 mM NaCI, 5% nonfat dry milk for 10 min, after which the cells were incubated for 1 h with anti-desmin monoclonal antibody (diluted 1:50) at 37°C and treated with goat anti-mouse IgG-fluorescein isothiocyanate (Sigma Chemical Co.). The secondary antibody was titrated to prevent nonspecific background fluorescence. The cells were rinsed in deionized water and placed cell-side down in mounting solution (90% glycerol in PBS) containing 0.1% p-phenylenediamine added to reduce photobleaching of the fluorescent stains during microscopy.
Reagents and statistical methods. All reagents were purchased from Sigma Chemical Co. unless otherwise indicated below. Results are expressed as mean±SEM. Analysis of variance and the Newman-Keuls test were used for multigroup comparisons. Values of P < .05 were considered statistically significant.
Results
The AngII binding assay was performed with '25I-AngII for cardiac fibroblasts and with '25I-Sar' Ile8 AngII for cardiomyocytes, because it has been shown that using these different 25I-ligands, neonatal rat cardiac fibroblasts (22) diomyocytes. As shown in Fig. 2 , in contrast to the data from the cardiac fibroblasts, cardiomyocytes substantially expressed both ATl-R and AT2-R through embryonal and neonatal stages: the ATI antagonist (10 ,uM) inhibited the binding by 59±3% (El9), 62±4% (1 d), and 63±4% (7 d), while the AT2 antagonist (10 MzM) caused 40±4% (E19), 29±3% (1 d), and 31±4% (7 d) inhibitions, respectively. Fig. 3 A shows the change in the AngIl receptor density and the subtype expression profiles in E 19 and l-d neonatal rat cardiac fibroblasts. The AngI, receptor densities in E 19 cardiac fibroblasts are significantly higher (P < 0.01, 1.4-fold) as compared with those in l-d fibroblasts, while ATI-R densities do not significantly change (524±31 fmol/mg protein at El9 to 549±33 fmol/mg protein at 1 d) and AT2-R densities are dramatically decreased (305±23 fmol/mg protein to 41 ± 12 fmol/ mg protein) in l-d neonates. The binding affinity was similar in El 9 and neonatal rat cardiac fibroblasts (Table I ). This indicates that the remarkable decrease in the AngII receptor density that occurs in l-d cardiac fibroblasts is mainly attributed to the change in AT2-R expression. The unchanged AT1-R expression during embryonic and neonatal period was examined at the mRNA level using quantitative RT-PCR, because ofthe low level ofAT I -R mRNA expression in the cardiac fibroblasts and cardiomyocytes. The validity of the quantitative RT-PCR analysis for AT1-R gene has already been established by our group (3) and by Iwai et al. (34) . As shown in Fig. 3 B, the RT-PCR assay indicates that the AT1-R mRNA levels in E19 and 1 -d rat cardiac fibroblasts are very similar, which is consistent with the results of the binding assay. On the other hand, the AT1-R has two subtypes (AT la-R and ATIb-R) with high homology as well as similar binding and functional characteristics (7, 13) . Because the PCR primers used in the RT-PCR assay for AT 1-R mRNA levels are designed from the oligonucleotides common to AT la-R and ATIb-R cDNA sequences, the amplified AT I -R signals reflect both AT I a-R and AT b-R mRNA levels. Therefore, we designed primers specific for AT I a-R or AT lb-R sequences to examine the subtype mRNA levels. As shown in Fig. 3 C, the embryonal day 19 and neonatal rat cardiac fibroblasts expressed both ATla-R and ATIb-R mRNAs. The ATla-R mRNA level is higher (approximately AnglI receptor density was calculated from the Scatchard analysis ofthe competitive binding curves shown in Fig. 1 ninefold) than that of AT lb-R in E 19 fibroblasts and this expression pattern was unchanged throughout the embryonal and neonatal periods. Fig. 4 A shows the changes in AngII receptor density and subtype in El9 and 1-day rat cardiomyocytes: AngII receptor densities are significantly (P < 0.05) decreased from 465±51 (E19) to 357±61 fmol/mg protein ( l-d), whereas the proportion of AT I-R is unchanged and the AT2-R density is decreased (from 178±14 to 87±9 fmol/mg protein). This developmental regulation profile of subtype expression is comparable with that in the cardiac fibroblasts except that the proportion of AT2-R expression is more remarkably reduced in l-d cardiac fibroblasts. As shown in Fig. 4 B, the ATI-R mRNA levels in E 19 and 1 -d rat cardiomyocytes were not significantly changed, which was in agreement with the results of the binding assay. The AT 1 a-R and AT lb-R mRNA levels in the cardiomyocytes were analyzed by RT-PCR (Fig. 4 C) . The ratios of ATla-R mRNA to ATla-R + ATlb-R mRNAs were 42±7% (E19) and 43±6% (l-d), suggesting that the ATlb-R mRNA level expressed in cardiomyocytes slightly predominates over that of AT 1 a-R in contrast to the expression profile in cardiac fibroblasts.
It has been reported that the proportion of ATI-R and AT2-R subtype expression in embryonal rat skin fibroblasts changes during culture (35) . As diac fibroblasts obtained by pre-plating were maintained for 2 d, passaged with trypsin, then seeded on plates. Fig. 5 shows the expression profiles of the AT I -R and AT2-R subtypes in E 19 and l-d cardiac fibroblasts during culture. The total AngIl receptor densities did not significantly change and the proportions of AT1-R and AT2-R remained constant for 8 d in culture after the second dispersion. The ATla-R and ATlb-R mRNA levels were also unchanged during the culture (data not shown). Thus, unlike the embryonal rat skin fibroblasts, the embryonal and neonatal cardiac fibroblasts stably expressed AT1-R (including AT la and ATlb) and AT2-R during culture. Because cardiac fibroblast-and cardiomyocyte-rich cultures were potentially cross-contaminated, staining with a monoclonal antibody against desmin, a cytoskeletal protein of cardiomyocytes, was used to identify cardiomyocytes. Fibroblast-rich cultures were relatively free of cardiomyocytes and cardiomyocyte-rich cultures were contaminated with about 5-10% fibroblasts (data not shown), consistent with the previous studies (20, 22, 24) .
To investigate the effects ofglucocorticoids on AngII receptors, l-d cardiac fibroblasts were incubated with 1 uM dexamethasone for 4-24 h. As shown in Fig. 6 , the AngII receptor density was significantly increased after 8-24 h of exposure to dexamethasone and progressively increased by -1.8-fold at 24 h, while the Kd values did not significantly change during the The AngII receptor density and proportion of ATI and AT2 were determined as described in Fig. 3 A. The experimental conditions, data numbers, and statistical methods are same as those in Fig. 1 . *P < 0.0I vs. E19 value. (B) ATl-R mRNA levels were determined by reverse-transcriptase PCR as described in Fig. 3 B. (C) ATla-R and ATlb-R mRNA levels were evaluated in the way same as described in Fig. 3 C. An experiment was performed using total RNA from cells obtained by a single preparation. exposure. It should be noted that ATl-R expression was increased by dexamethasone, whereas AT2-R expression was unaffected at 24 h (Fig. 7 A) . The steady-state mRNA level of ATI-R was measured by RT-PCR (Fig. 7 B) . Since the a-tubulin mRNA level was significantly unchanged throughout the experimental period, we used cx-tubulin mRNA as an internal RNA control. The relative value normalized with deletion mutated cRNA and a-tubulin signals indicated that the increase in the ATI-R mRNA level was 1.91±0.12-fold at 24 h. The effects ofdexamethasone on ATla-R and ATlb-R mRNA levels were studied (Fig. 7 C) . ATla-R mRNA accumulation was exclusively induced as compared to that in the absence ofdexamethasone, whereas changes in AT 1b-R mRNA were not significant. RU38486, a specific glucocorticoid antagonist, completely inhibited the increases of ATla-R at the protein and mRNA levels induced by dexamethasone (Fig. 7, A and B) . We determined whether dexamethasone increased AT a-R mRNA levels through a transcriptional or a posttranscriptional mechanism. To investigate this, a nuclear run-offtranscription assay was performed and the stability of ATla-R mRNA was examined. As shown in Fig. 8 A, the transcriptional rate of ATla-R gene relative to that of f3-actin gene increased 1.96±0.23-fold in dexamethasone-treated cells. The rate of transcription of ,3-actin gene was not altered with dexamethasone as previously reported (36) . This change corresponded with the increase in ATla-R mRNA levels evaluated by RT-PCR. The AT I a-R mRNA turnover was examined by inhibit- ing new mRNA transcription with actinomycin D (Fig. 8 B) . A half-life of 18±0.7 h for ATl a-R transcript was obtained in the absence ofthe steroid. The half-life was unchanged in the presence of dexamethasone up to 36 h.
Discussion
The renin-angiotensin system is an important determinant of cardiovascular homeostasis. Recent evidence indicates that AngII is involved in mitogenesis and/or hypertrophy as well as in stimulating the heart rate and affecting cardiac contractility ( 14) . For example, AngHI stimulates hypertrophy in adult rat cardiomyocytes and expression of the early growth response gene in adult rat cardiomyocytes (24, 37) . A series ofstudies by Baker and co-workers have revealed that rat neonatal cardiac fibroblasts express the functional Ang1I receptors, AngI, AngII, and ACE as a component of the local renin-angiotensin system in the heart (20, 22) . Several animal studies have shown that treatment with an ACE inhibitor prevents myocardial fibrosis in a rat model with renovascular hypertension (38) and with induced myocardial infarction (39) . In the latter study, collagen accumulation and DNA synthesis were prevented by the ACE inhibitor. This evidence suggests that cardiac fibroblasts are a target of AngII, and that AngII plays a role in the structural remodeling ofthe cardiac interstitium by exerting a proliferative effect on fibroblasts.
Our present data showed for the first time, that rat cardiac fibroblasts in culture consistently express ATla-R rather than ATlb-R during development from the late embryo to the neonate, and that the expression of AT2-R is dramatically repressed immediately after birth. An increase in the total number of AngHI receptors in embryonal rat cardiac fibroblasts was shown to be due to an increase in the number of AT2-R. In contrast, the substantial expression ofboth ATl-R and AT2-R in the cardiomyocytes in culture was maintained during development, in which the expression of AT2-R is significantly increased in E19 cardiomyocytes as compared to that during the neonatal period, resulting in an increase of total AngIl receptor 1598 Matsubara et al. numbers in E19 cardiomyocytes. The expression of ATlb-R mRNA in cardiomyocytes, unlike cardiac fibroblasts, predominates over the AT I a-R mRNA level and this expression profile was consistently observed through the embryonal and neonatal period. A previous study (22) that used a cell preparation procedure very similar to ours, showed that the contamination of vascular smooth muscle cells in cardiac fibroblast cultures is < 5% and that there is no contamination ofendothelial cells in fibroblast cultures. Because it is impossible to eliminate fibroblast contamination from cardiomyocyte cultures (< 10% with desmin staining) and because the fibroblasts predominantly possess ATIa-R rather than ATlb-R, the actual proportion of AT I b-R expressed in cardiomyocytes might be more than that estimated in this study. Thus, the expression profile for ATI-R (including ATla-R and ATlb-R) and AT2-R is quite distinct between cardiac fibroblasts and cardiomyocytes in culture, indicating that the expression of AngII receptors is regulated in a cell-specific manner in the heart as well as in a subtype-specific manner.
The ATl-R mediates AngII-induced alterations in cardiovascular responses, catecholamine and aldosterone secretion, and drinking behavior (2) . Although the potential function and cDNA structure of the AT2-R remains unpublished, Grady et al. ( 17) have suggested an AT2-R mediating effect of AngIl on fetal development, by providing evidence that the AT2-R abundantly expressed in mesenchymal cells sharply decreases postparturition and that the AT l -R is consistently present in the fetus with a tissue distribution identical to that found in the adult animal. These expression profiles appear to be very similar to those observed in cardiac fibroblasts and cardiomyocytes. Such developmental changes were also reported in the human study in which ventricular AngII-binding density in 1-d-old baby was 10-fold higher than that in adult heart, although the receptor subtype was not determined (40) . An in situ autoradiographic study has shown that the proportion of ATl-R and AT2-R in the E 19 rat heart is nearly equal (4). We also revealed using a membrane binding assay, that the neonatal rat heart expresses ATl-R and AT2-R in equal amounts, and that cardiac hypertrophy stimulates expressions of both subtypes at the mRNA and protein levels (3) . In addition, an ATl-R antagonist completely inhibited the development of hypertrophy, whereas the AT2-R antagonist did not affect the magnitude of hypertrophy. These accumulated findings suggest that in the rat heart, the AT2-R is important during fetal development and that the ATl-R is closely involved in the growth or hypertrophic responses of the mature heart in the postnatal period. The findings that balloon angioplasty enhances the expression of ATl-R in the neointima of the rat aorta (41 ) or that a venous bypass graft induced ATl -R expression in the myointimal thickening segment (42) may support our hypothesis. Further study, including molecular characterization of AT2-R would be required.
The rat AT1-R have at least two subtypes (AT la-R and ATlb-R), which exhibit high similarity in amino acid sequence (95% identity), binding ofAngII analogues and utilization of Ca++ as an intracellular second message (7, 13) . The adrenal, pituitary, and uterus primarily express AT lb-R mRNA, whereas vascular smooth muscle, kidney, and cerebrum express primarily AT I a-R mRNA (7, 13) . In the human study, Mauzy et al. ( 10) have reported that the subtype in ATI-R exists in the human gene, whereas Yoshida et al. ( 12) have shown that human has a single class ofAT1-R gene. Thus, there are discrepant results with respect to the presence of human ATl-R subtype. In the adult rat heart, it is reported that the ratio ofAT I a-R mRNA to AT I b-R mRNA is 1.2 by Iwai et al. (34) (30) . In the present study, we demonstrated that cardiac fibroblasts exclusively express ATla-R, while in cardiomyocytes the proportion of ATlb-R mRNA is higher than that of AT la-R mRNA. Iwai and Inagami (7) and Kakar et al. (13) have proposed that AT lb-R mediates endocrine function such as the secretion of aldosterone from the adrenal gland, and adrenocorticotropic hormone and prolactin from the pituitary gland, because of its localized distribution in the rat tissue. The cardiomyocytes secrete atrial natriuretic factor (ANF), whereas ANF granules are not present in cardiac fibroblasts (43, 44) . It has been reported that AngII directly stimulates ANF secretion from neonatal rat cardiomyocytes, but not from cardiac fibroblasts (43) . Supposing the ATlb-R could mediate endocrine function as proposed by Kakar et al. on the basis of its tissue distribution (7, 13) , the AngII effect mediated by cardiac AT lb-R may be involved in ANF secretion from cardiomyocytes. However, this could be unlikely, because AT I a-R and AT I b-R have a high similarity in the receptor-mediating function (7, 13) . The development of an AT lb-R specific antagonist would be important to establish this claim.
In most steroid-regulated genes, gene expression is mainly influenced by changing the transcription rate (45), but significant differences in the stability of mRNA such as that of ovalbumin mRNA in the presence of estrogen (46) , have been reported. In the present study, the RT-PCR assay demonstrated using the primers specific for ATla-R or ATlb-R gene, that the ATla-R mRNA level is increased by 2.1-fold in the presence of dexamethasone, whereas the AT 1 b-R mRNA level is unchanged by dexamethasone. The increase in dexamethasone-induced transcription, measured by the run-off assay, was in good agreement with the increase in ATla-R transcript determined by the RT-PCR assay. The half-life of AT I a-R transcript (Fig. 8 B) or ATlb-R transcript (data not shown) was unaffected by dexamethasone. Although the ATla-R cDNA probe used in the run-off assay could hibridize to the transcript ofATlb-R gene because of its highly homologous sequence (7, 13) , these findings suggest that AT la-R gene is responsive to dexamethasone at the transcriptional level and AT Ib-R gene is not regulated by dexamethasone. Glucocorticoids are involved in the regulation of blood pressure (27) , and enhancement of vascular responsiveness has been considered one of the major contributing factors in glucocorticoid-induced hypertension (28) . It has been reported that the expression of a 1 B-adrenergic receptor (36) or vasopressin receptor (V1 subtype) (47) is also increased by dexamethasone. Since the vascular smooth muscle cells express a substantial amount of ATla-R (5), the overexpression of these vasoactive substances receptors may be involved in vascular hyperreactivity in glucocorticoid-induced hypertension such as Cushing's disease. These possibilities would require direct experimental testing in animals possibly including humans.
